A review of the Cochrane COVID-19 Study Register reveals inconsistency in the choice and measurement of SARS-CoV-2 infection outcomes in prevention trials [version 1; peer review: 1 approved]

Susanna Dodd¹, Sarah Gorst¹, Kerry Avery², Nicola Harman¹, Rhiannon Macefield², Paula Williamson¹, Jane Blazeby², COS-COVID-P Steering Committee

¹Department of Health Data Science, University of Liverpool (a member of Liverpool Health Partners), Liverpool, L69 3GL, UK
²NIHR Bristol and Weston Biomedical Research Centre, Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, BS8 2PS, UK

Abstract

Background: Multiple studies are evaluating how to prevent SARS-CoV-2 infection. Interventions are wide ranging and include vaccines, prophylactic drugs, public health safety measures, and behavioural interventions. Heterogeneity in the outcomes measured and reported is leading to research waste and inefficiency, slowing worldwide identification and implementation of effective methods to prevent infection. A core outcome set (COS) for studies of interventions to prevent SARS-CoV-2 infection has recently been developed, identifying infection as a critical outcome to measure. This paper examines how SARS-CoV-2 infection outcomes are measured in registered COVID-19 prevention trials and considers how this can be improved.

Methods: We searched the Cochrane COVID-19 Study Register to identify and review SARS-CoV-2 infection outcomes in prevention trials, including the rationale for choice of outcome measurement. We included phase 3 and 4 trials of COVID-19 prevention interventions. Early phase trials and studies relating to the transmission, treatment or management of COVID-19 were excluded.

Results: We identified 430 entries in the register, of which 199 unique prevention trials were included across eight settings and 12 intervention types. Fifteen (8%) trials did not include any SARS-CoV-2 infection outcomes. The remaining 184 (92%) studies included a total of 268 SARS-CoV-2 infection outcomes, of which 32 (17%) did not specify how infection would be measured. Testing (i.e. formal

Open Peer Review

Approval Status ✓

version 1
28 May 2021
https://doi.org/10.12688/f1000research.52491.1

Any reports and responses or comments on the article can be found at the end of the article.
diagnostic test) as a standalone method for determining infection was used in 57 (31%) trials, whereas defining infection by symptoms alone was used in 16 (9%) trials. All other trials (n=79, 43%) included multiple infection outcomes, defined in different ways.

**Discussion:** There is considerable variation in how SARS-CoV-2 infection is measured within and across different interventions and settings. Furthermore, few studies report the rationale for outcome selection and measurement. Better transparency and standardisation of SARS-CoV-2 infection measurement is needed for the findings from prevention trials to inform decision-making.

**Keywords**
SARS-CoV-2, infection, outcomes, outcome measurement, COVID-19, prevention, trials

This article is included in the Emergent Diseases and Outbreaks gateway.

This article is included in the Coronavirus collection.

**Corresponding author:** Susanna Dodd (shinds@liverpool.ac.uk)

**Author roles:** Dodd S: Formal Analysis, Investigation, Writing – Review & Editing; Gorst S: Investigation, Writing – Original Draft Preparation; Avery K: Investigation, Writing – Review & Editing; Harman N: Investigation, Writing – Review & Editing; Macefield R: Investigation, Writing – Review & Editing; Williamson P: Conceptualization, Supervision, Writing – Review & Editing; Blazeby J: Conceptualization, Supervision, Writing – Review & Editing;

**Competing interests:** JMB and PRW are members of the COMET Management Group. All other authors disclose no competing of interest.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2021 Dodd S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Dodd S, Gorst S, Avery K et al. A review of the Cochrane COVID-19 Study Register reveals inconsistency in the choice and measurement of SARS-CoV-2 infection outcomes in prevention trials [version 1; peer review: 1 approved]
F1000Research 2021, 10:426 https://doi.org/10.12688/f1000research.52491.1

**First published:** 28 May 2021, 10:426 https://doi.org/10.12688/f1000research.52491.1
Introduction
Coronavirus disease 2019 (COVID-19), resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has significant morbidity and mortality. Addressing human-to-human transmission of SARS-CoV-2 is a global research priority. Research to fully understand the modes of transmission of SARS-CoV-2 is ongoing. Studies to prevent the spread of SARS-CoV-2 are increasing, with more than 1000 studies registered between December 2020 and February 2021. Interventions are wide ranging, including public health measures such as lockdown of countries/cities, closure of schools and public places, social distancing measures and handwashing, interventions in primary and secondary care practice such as the use of personal protective equipment (PPE) and increased time for appointments/interventions, alongside the development of effective vaccines and drugs to prevent disease.

Evidence is accumulating to evaluate the effectiveness of prevention interventions, but limitations in evidence synthesis have been identified because of inconsistent selection, measurement and reporting of outcomes in the studies. Whilst studies primarily focus on mitigating the risk of contracting COVID-19, they may measure other outcomes relevant to the population of interest and type of intervention, for example, educational outcomes in studies of school closures and studies primarily focus on mitigating the risk of contracting COVID-19, they may measure other outcomes relevant to tolerance/acceptability in studies of PPE use in secondary care. However, unnecessary heterogeneity in the outcomes measured and reported in COVID-19 prevention trials leads to research waste and inefficiency. For example, a recent commentary highlighted the rarity of randomised trials of public health interventions for COVID-19, which is likely due to the need for unattainably large sample sizes. Fretheim argues that underpowered trials in public health should be regarded as contributions to the larger body of evidence on COVID-19. However, for underpowered trials to be collectively assessed and synthesised in systematic reviews they need to be measuring the same outcomes.

A solution to this issue is to develop a core outcome set (COS), which is defined as an agreed standardised set of outcomes that should be measured and reported, as a minimum, in all clinical research studies in a specific area of health care to address inconsistencies in outcome measurement. The COS-COVID-P study, in collaboration with an international and multidisciplinary committee of experts and public contributors, has developed a COS for studies of interventions to prevent SARS-CoV-2 infection. During the COS development process, online workshops were held to consider the evidence on COVID-19 prevention and the issue of outcome heterogeneity. More than 70 key international stakeholders, including clinicians, researchers, public representatives, methodologists, systematic reviewers, guideline developers, and regulatory agency representatives shared their expert opinions. Agreement on the final COS was reached in August 2020. Two outcome domains were identified as being essential to all COVID-19 prevention studies: infection and intervention-specific harms. How to measure these outcomes now requires consideration and led to this paper.

SARS-CoV-2 infection can be measured through laboratory testing, symptom assessment or a combination of both. However, there is no single standalone diagnostic test nor agreement on diagnostic symptoms. Thus, there is a pressing need to consider how to assess SARS-CoV-2 infection uniformly across studies to optimise data reporting and synthesis. The aim of this study is to review SARS-CoV-2 infection outcomes in registered COVID-19 prevention trials and examine the reported rationales for choice of outcome measurement. Our intention is that this will inform optimal methods for the design of future studies.

Methods
Search strategy
For the purposes of the review presented here, we searched the Cochrane COVID-19 Study Register https://covid-19.cochrane.org/ on 24 November 2020. The Cochrane COVID-19 Study Register is a freely available, annotated reference collection of primary research studies on COVID-19, including interventional, observational, diagnostic, prognostic, epidemiological and qualitative designs. The register is continually updated to support rapid evidence synthesis, and includes studies from multiple data sources including Clinicaltrials.gov, the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, medRxiv, PubMed and the WHO International Clinical Trials Registry Platform (ICTRP). We restricted our Cochrane COVID-19 Study Register search results by study type (“interventional”), study design (“parallel/crossover”), intervention assignment (“randomised”) and study aim (“prevention”). The Cochrane COVID-19 Study Register defines prevention studies as those aiming to assess one or more interventions for preventing the development of a specific disease or health condition.

Eligibility criteria
We included phase three and four trials of prevention interventions for COVID-19. We excluded phase one and two trials, including those that used other terms to imply that they were early phase (e.g. “explorative”), because these trials focus on safety, rather than the effectiveness of an intervention. Studies relating to the transmission, treatment or management of COVID-19 were also excluded. Studies identified from the Cochrane COVID-19 Study Register search were split equally between five experienced systematic reviewers (KA, SD, SG, NH, RM), who assessed the eligibility of their cohort of studies according to these eligibility criteria.
Data extraction

Data from eligible trials were extracted using a piloted, standardised data extraction spreadsheet, with the work split equally between five experienced systematic reviewers (KA, SD, SG, NH, RM). In cases of any ambiguity or doubt, queries were assessed by SD. Any queries were discussed with the whole team who collectively reached agreement on how to progress. The following data were extracted for each study: intervention type (e.g. drug, vaccine, behavioural), intervention (as described verbatim), setting (i.e. population of interest), SARS-CoV-2 infection outcomes (as described verbatim), SARS-CoV-2 infection outcome definition (i.e. how SARS-CoV-2 infection would be measured), whether or not the SARS-CoV-2 infection outcome was specified as being a primary or secondary outcome, and the rationale provided for SARS-CoV-2 infection outcome measurement selection. In addition, the reviewers recorded whether the study record related to a registry entry, trial protocol or the main report. If the registry entry record provided a link to a study protocol, this protocol was also reviewed, and the relevant data extracted.

Data analysis

Extracted data were summarised according to the number of SARS-CoV-2 infection outcomes per trial. For trials that included one SARS-CoV-2 infection outcome, data were summarised according to the single outcome definition specified in each trial (i.e. testing, symptoms, testing or symptoms, testing and symptoms). For trials that included multiple SARS-CoV-2 infection outcomes, data were summarised according to each outcome definition combination. For example, some trials may have measured one SARS-CoV-2 infection outcome using testing alone, a second SARS-CoV-2 infection outcome by symptoms alone and a third SARS-CoV-2 infection outcome by testing and symptoms. In addition to analysing the data by the overarching outcome definition (e.g. testing), we also summarised the data according to the specific underlying definition. For example, a trial would be summarised as having two versions of testing if they specified that one SARS-CoV-2 infection outcome was determined by reverse-transcriptase polymerase chain reaction (RT-PCR), and another SARS-CoV-2 infection outcome was determined by serology (antibodies, seroconversion, seroprevalence). The categorisation of outcome definitions was based on the verbatim text available in the registry records. Analysis was carried out using Stata version 16.1.

Results

Search results

Our searching of the Cochrane COVID-19 Study Register returned 430 records that were screened for eligibility, of which 231 were excluded. A total of 199 unique prevention trials were identified (Figure 1).

Trial characteristics

Of the 199 eligible trials, 176 (88%) had a trial registry record only. The remaining 23 trials had registry records plus a protocol (n = 15, 8%) or journal article (n = 6, 3%) or both a protocol and journal article (n = 2, 1%). Most trials examined drug prophylaxis (n = 92, 46%) or vaccine (n = 54, 27%) interventions. Other interventions included dietary supplements (n=20, 10%), behavioural/social distancing (n = 12, 6%) and PPE or other physical barriers (n = 7, 4%). Fourteen (7%) trials evaluated other interventions that included Ayurveda, homeopathy, traditional Chinese medicine, a medicinal plant, Unani, telehealth and financial support.

The trials were undertaken across eight combinations of setting and population of interest, with almost half (n = 98, 49%) in healthcare workers. Other settings included adults in the community (n = 45, 23%), high risk groups (e.g. elderly, hospitalised, or specific disease; n = 21, 11%), people in close contact with COVID-19 cases (e.g. family members; n = 16, 8%), nursing home residents and/or staff (n = 10, 5%), people with potential exposure to COVID-19 (n = 5, 3%), police (n = 3, 2%) and schools (n = 1, <1%). The characteristics of included trials are described in Table 1.

SARS-CoV-2 infection outcomes

Of the 199 trials, 15 (8%) did not include any SARS-CoV-2 infection outcomes. These 15 studies predominantly evaluated behavioural (n = 8, where interventions were ‘STOP touching your face’ mindfulness online training programme; Brief informational infographic; E-E video about COVID hygiene; Mental Imagery; Digital health literacy intervention; e-learning module; Telepsychoeducation with personalized videos; combined video display and live demonstration as training methods to healthcare providers for donning and doffing PPE) or PPE/physical barrier (n = 3) interventions, with the remaining four trials evaluating social distancing, dietary supplements, a medicinal plant and homeopathy. Examples of outcomes recorded in trials that did not include a SARS-CoV-2 infection outcome included frequency of face-touching behaviour in a behavioural intervention trial and contamination of any part of the base clothing or exposed skin of the upper body in a PPE trial.

A total of 268 SARS-CoV-2 infection outcomes were identified across 184 (92%) trials, with infection measured as a primary outcome in 149 (81%) studies. Table 2 provides the outcome definitions recorded. We categorised outcome
definitions using the verbatim text available in the registry records. In 118 (64%) trials, a single infection outcome was included. Fifty (27%) trials included two infection outcomes, 14 (8%) included three infection outcomes and two (1%) included four infection outcomes. Examples of multiple infection outcomes within the same trial are provided in Table 2. Table 3 lists the specific outcome definitions across the 184 trials.

Forty-five (25%) trials defined infection in non-specific terms (e.g. “COVID”, “SARS-CoV-2 infection”, “infected”, “confirmed”), without specifying how infection would be/was determined (i.e. via a specific test to be undertaken or symptoms to be recorded). In 32 of these trials (17% of all included trials), the non-specific infection term was the only infection outcome listed. Figure 2 displays the number of trials with non-specific COVID outcomes by month of registration. Of the 45 trials with non-specific COVID outcomes, 23 (51%) trials were registered within the first three months (March to May 2020) of the COVID-19 outbreak being declared a global pandemic.

Testing was the only means employed for determining infection in 57 (31%) trials, whereas relying on symptoms alone to define infection occurred in 16 (9%). All other trials included multiple infection outcomes, defined in different ways (Table 2). Where one of the infection outcomes was to be determined by testing alone (n = 96), this was most commonly by RT-PCR (n = 36, 20%) and serology (n = 22, 12%) tests. Where infection was defined on the basis of symptoms alone (e.g. symptomatic COVID-19) (n = 45), the number of symptoms and definitions varied (Tables 4 and 5). Some trials included outcomes defined by combinations of testing and/or symptoms: 13 (7%) using either testing or symptoms to determine infection; 46 (25%) specifying both testing and symptoms must be positive to define infection (e.g. RT-PCR and symptomatic).

SARS-CoV-2 infection outcomes by setting and intervention type

Tables 6 and 7 detail the use of various SARS-CoV-2 infection outcome definitions by setting and intervention type, respectively.
Table 1. Trial characteristics (n = 199).

| Publication sources                                      | Number (%) |
|----------------------------------------------------------|------------|
| Trial registry record only                               | 176 (88.4) |
| Trial registry record + protocol                         | 15 (7.5)   |
| Trial registry record + journal article                  | 6 (3)      |
| Trial registry record + protocol + journal article       | 2 (1)      |

| Intervention types                                       |            |
|----------------------------------------------------------|------------|
| Drug prophylaxis                                         | 92 (46.2)  |
| Vaccine                                                  | 54 (27.1)  |
| Dietary supplement                                       | 20 (10.1)  |
| Behavioural/social distancing                            | 12 (6.0)   |
| Personal protective equipment or other physical barrier  | 7 (3.5)    |
| Other                                                    | 14 (7.0)   |
| Ayurveda                                                 | 5 (2.5)    |
| Homeopathy                                               | 4 (2.0)    |
| Chinese medicine                                         | 1 (0.5)    |
| Medicinal plant                                          | 1 (0.5)    |
| Unani                                                    | 1 (0.5)    |
| Telehealth                                               | 1 (0.5)    |
| Financial support                                        | 1 (0.5)    |

| Setting                                                  |            |
|----------------------------------------------------------|------------|
| Health care workers                                      | 98 (49.3)  |
| Community/adults                                         | 45 (22.6)  |
| High risk groups (e.g. elderly, hospitalised, or specific disease) | 21 (10.6) |
| In close contact with COVID case (e.g. family members)   | 16 (8)     |
| Nursing home                                             | 10 (5)     |
| Potentially exposed to SARS-CoV-2                        | 5 (2.5)    |
| Police                                                   | 3 (1.5)    |
| Schools                                                  | 1 (0.5)    |

| SARS-CoV-2 infection outcomes measured/reported in the trial |            |
|--------------------------------------------------------------|------------|
| No SARS-CoV-2 infection outcomes                            | 15 (7.5)   |
| Single SARS-CoV-2 infection outcome                         | 118 (59.3) |
| Two SARS-CoV-2 infection outcomes                           | 50 (25.1)  |
| Three SARS-CoV-2 infection outcomes                         | 14 (7.0)   |
| Four SARS-CoV-2 infection outcomes                          | 2 (1.0)    |

1Seven of these studies also included others in close contact with COVID cases (two of which also included high risk groups); a further two of these studies included others with potential exposure to COVID (one of which also included police).
2Or equivalent term.
3In 32 (16.1%) studies, the single COVID outcome was a non-specific term.

Rationale provided for SARS-CoV-2 infection outcome selection/definition

Of the 184 trials that included SARS-CoV-2 infection outcomes, seven provided a rationale for their choice of outcome selection and/or measurement (see Table 8). Of these seven studies, this was often to justify their specific choice of testing, with one drug prophylaxis trial explaining that “testing and criteria for diagnosis COVID-19 is likely to rapidly evolve over the course of this trial and will vary internationally” and a school closure trial basing outcome measures on routinely collected testing data to ensure “feasibility, facilitate speed, and limit costs.” A drug prophylaxis trial in
healthcare workers argued that relying on symptoms consistent with infection without laboratory confirmation raises “concerns of type II error from asymptomatic participants”. Conversely, another drug prophylaxis trial justified the decision to use symptoms given issues of access to testing, “Given limited availability of outpatient PCR testing in many jurisdictions during our study period, particularly in April 2020, probable Covid 19 based on Covid-19-compatible symptoms was included in the composite primary endpoint”.

Discussion
We have reviewed COVID-19 prevention trials that were registered in the first nine months of the pandemic and examined in detail their rationale, selection and method of measuring SARS-CoV-2 infection. Of the 199 included trials,

| Table 2. SARS-CoV-2 infection outcome definitions, by number of infection outcomes per trial. |
|---------------------------------|------------------|
|                                  | Number of trials (% of 184) |
| **One SARS-CoV-2 infection outcome per trial**¹ | 118 (64.1) |
| Testing alone                   | 49 (26.6) |
| Non-specific term for infection | 32 (17.4) |
| Symptoms alone                  | 16 (8.7) |
| Positive on both testing AND symptoms | 15 (8.2) |
| Positive on either testing OR symptoms | 6 (3.3) |
| **Two SARS-CoV-2 infection outcomes per trial**² | 50 (27.2) |
| Testing alone (2 versions)      | 7 (3.8) |
| Testing alone; Non-specific term for infection | 3 (1.6) |
| Testing alone; Symptoms alone   | 9 (4.9) |
| Testing alone; Testing AND symptoms | 12 (6.5) |
| Testing alone; Testing OR symptoms | 3 (1.6) |
| Symptoms alone; Non-specific term for infection | 7 (3.8) |
| Testing AND symptoms; Non-specific term for infection | 2 (1.1) |
| Symptoms alone; Testing AND symptoms | 3 (1.6) |
| Symptoms alone; Testing OR symptoms | 2 (1.1) |
| Testing AND symptoms (2 versions) | 2 (1.1) |
| **Three SARS-CoV-2 infection outcomes per trial**³ | 14 (7.6) |
| Testing alone (3 versions)      | 1 (0.5) |
| Testing alone (2 versions); Symptoms alone | 2 (1.1) |
| Testing alone (2 versions); Testing AND symptoms | 2 (1.1) |
| Testing alone; Symptoms alone; Testing AND symptoms | 2 (1.1) |
| Testing alone; Symptoms alone; Non-specific term for infection | 1 (0.5) |
| Testing alone; Testing AND symptoms; Testing OR symptoms | 1 (0.5) |
| Testing alone; Testing AND symptoms (2 versions) | 2 (1.1) |
| Symptoms alone; Testing AND symptoms (2 versions) | 2 (1.1) |
| **Four SARS-CoV-2 infection outcomes per trial**⁴ | 2 (1.1) |
| Testing alone; Symptoms alone; Testing AND symptoms (2 versions) | 1 (0.5) |
| Testing AND symptoms (3 versions); Testing OR symptoms | 1 (0.5) |

¹Note that when the same COVID outcome definition was measured at multiple time points or analysed in multiple ways (e.g. as a binary outcome AND a time to event outcome), these repetitions were considered as a single COVID outcome for the purpose of this review.
²Example of two infection outcomes: ‘Number of people turning symptomatic’ and ‘Number of people turning Covid19 positive’ (see: http://www.ctri.nic.in/Clinicaltrials/gmaindet2.php?trialid=44963).
³Example of three infection outcomes: ‘positive serology or RT-PCR for COVID-19 up until day 28’ , ‘positive serology at day 28’ and ‘symptoms of COVID-19’ (see: https://clinicaltrials.gov/ct2/show/NCT04342156).
⁴Example of four infection outcomes: ‘Number of symptomatic infections confirmed by SARS-CoV-2 (COVID-19)’, ‘Severity of SARS-CoV-2 (COVID-19) infection’ and ‘Duration of symptoms of COVID-19 coronavirus infection’ (see: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001530-35/ES).
Table 3. SARS-CoV-2 infection outcome definitions.

| Non-specific term for infection (no explicit test/symptoms detailed) | Number of trials with ≥1 outcome (% out of 184) | Number of outcomes (% out of 268) |
|---|---|---|
| COVID | 45 (24.5) | 45 (16.8) |
| SARS-Cov-2 infection | 29 (15.8) | 29 (10.8) |
| infected | | |
| confirmed | 16 (8.7) | 16 (6.0) |
| documented | | |

**Confirmed with testing alone**

| | 96 (52.2) | 110 (41.0) |
| --- | --- | --- |
| positivity (positive disease/test) | 13 (7.1) | 13 (4.9) |
| antigen test | 1 (0.5) | 1 (0.4) |
| swab | 2 (1.1) | 2 (0.7) |
| lab confirmation | 9 (4.9) | 9 (3.4) |
| microbiologically confirmed | 1 (0.5) | 1 (0.4) |
| molecular test | 1 (0.5) | 1 (0.4) |
| RT-PCR | 36 (19.6) | 36 (13.4) |
| serology (antibodies, seroconversion, seroprevalence) | 22 (12.0) | 23 (8.6) |
| RT-PCR OR serology | 16 (8.7) | 16 (6.0) |
| test OR seroconversion | 2 (1.1) | 2 (0.7) |
| virology OR serology | 3 (1.6) | 3 (1.1) |
| molecular OR serological test | 2 (1.1) | 2 (0.7) |
| RT-PCR AND SARS-Cov-2 test | 1 (0.5) | 1 (0.4) |

**Symptoms alone**

| | 45 (24.5) | 45 (16.8) |
| --- | --- | --- |
| symptomatic | 40 (21.7) | 40 (14.9) |
| clinical evidence | 2 (1.1) | 2 (0.7) |
| clinical disease without laboratory confirmation | 1 (0.5) | 1 (0.4) |
| confirmed via online questionnaire | 1 (0.5) | 1 (0.4) |
| confirmed OR probable | 1 (0.5) | 1 (0.4) |

**Testing OR symptoms**

| | 13 (7.1) | 13 (4.9) |
| --- | --- | --- |
| lab confirmation OR symptomatic | 2 (1.1) | 2 (0.7) |
| positive test OR symptomatic | | |
| asymptomatic OR symptomatic | 4 (2.2) | 4 (1.5) |
| microbiological test OR clinical features | 1 (0.5) | 1 (0.4) |
| RT-PCR OR symptomatic | 4 (2.2) | 4 (1.5) |
| RT-PCR OR serology OR symptomatic | 1 (0.5) | 1 (0.4) |
| molecular confirmation OR symptomatic | 1 (0.5) | 1 (0.4) |

**Testing AND symptoms**

| | 46 (25.0) | 55 (20.5) |
| --- | --- | --- |
| asymptomatic | 2 (1.1) | 2 (0.7) |
| lab confirmation AND asymptomatic | 3 (1.6) | 3 (1.1) |
| lab confirmation AND symptomatic | 8 (4.3) | 8 (3.0) |
| microbiologically confirmed AND symptomatic | 1 (0.5) | 1 (0.4) |
| microbiologically AND lab confirmed AND symptomatic | 1 (0.5) | 1 (0.4) |
268 SARS-CoV-2 infection outcomes were identified, across 184 studies. Of these, almost one fifth did not define how infection would be measured in the register entry, with the remaining studies specifying a combination of testing alone, symptoms alone, or testing and/or symptoms. Very few trials provided a rationale for the choice of how infection would be measured. The observed heterogeneity of outcome measurement of SARS-CoV-2 infection in COVID-19 prevention studies limits effective evidence synthesis and scientific comparison of interventions, which has enormous consequences for decision-making at an individual and public health level. We recommend that studies provide a rationale for choice of infection measurement and, if possible, that uniformity is agreed internationally on how to measure SARS-CoV-2 infection in trials of prevention interventions.

The heterogeneity of outcome measurement identified in the current study is not uncommon. A recent methodological systematic review revealed significant heterogeneity in the outcome measurement instruments used in trials evaluating therapeutic interventions for COVID-19, thus highlighting the need for greater consistency. However, such heterogeneity is not restricted to COVID-19 research studies. A multiplicity of outcome measurement instruments has recently

|                | Number of trials with ≥1 outcome (% out of 184) | Number of outcomes (% out of 268) |
|----------------|-----------------------------------------------|-----------------------------------|
| RT-PCR AND symptomatic | 21 (11.4)                                      | 21 (7.8)                          |
| (RT-PCR OR serology) AND asymptomatic | 1 (0.5)                                       | 1 (0.4)                           |
| (RT-PCR OR serology) AND symptomatic | 3 (1.6)                                       | 3 (1.1)                           |
| (RT-PCR OR molecular test) AND symptomatic | 2 (1.1)                                       | 2 (0.7)                           |
| (serology OR lab confirmed) AND symptomatic | 2 (1.1)                                       | 2 (0.7)                           |
| serology AND asymptomatic | 1 (0.5)                                       | 1 (0.4)                           |
| serology AND symptomatic | 2 (1.1)                                       | 2 (0.7)                           |
| (serology AND symptomatic) OR RT-PCR | 1 (0.5)                                       | 1 (0.4)                           |
| virologically-confirmed AND symptomatic | 2 (1.1)                                       | 2 (0.7)                           |
| test AND symptomatic | 4 (2.2)                                       | 4 (1.5)                           |
| molecular confirmation AND symptomatic | 1 (0.5)                                       | 1 (0.4)                           |

1Includes one study that specified individual symptoms only.
2Note that “symptomatic” includes references to clinical confirmation.

Figure 2. Trials with ≥1 non-specific SARS-CoV-2 infection outcome by month of registration (out of 184 trials with at least one SARS-CoV-2 infection outcome). Left-hand axis - number of trials. Right-hand axis - % of total number of trials.
Table 4. "Symptomatic" definitions provided for SARS-CoV-2 infection outcomes.

| “Symptomatic” definitions                                                                 |
|------------------------------------------------------------------------------------------|
| [https://clinicaltrials.gov/ct2/show/NCT04318015](https://clinicaltrials.gov/ct2/show/NCT04318015) “Symptomatic infection rate by COVID-19 defined as cough, dyspnea, fever, myalgia, arthralgias or rhinorrhea along with a positive COVID-19 real-time polymerase chain reaction test” |
| [https://pubmed.ncbi.nlm.nih.gov/33068425](https://pubmed.ncbi.nlm.nih.gov/33068425) “The definition of Covid-19-compatible symptoms was based on guidance from the US Council for State and Territorial Epidemiologists (Appendix) 1. Specifically, probable disease was defined as having cough, shortness of breath, or difficulty breathing, OR two or more of the following symptoms: fevers, chills, rigors, myalgia, headache, sore throat, new olfactory and taste disorders. Possible disease was defined as one or more COVID-19-compatible symptoms. Three blinded infectious diseases physicians independently adjudicated cases of symptomatic participants based on the above criteria.” |
| [http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105](http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105) “defined as self-reported fever or cough, or shortness of breath, or respiratory distress, or runny or blocked nose plus a positive PCR test and/or antibody test” |
| [https://clinicaltrials.gov/ct2/show/NCT04321174](https://clinicaltrials.gov/ct2/show/NCT04321174) “fever, cough or other respiratory/systemic symptoms (including but not limited to fatigue, myalgias, alterations in taste, shortness of breath, sore throat, headache, chills, coryza, nausea, vomiting, diarrhea) by day 14 in a patient with laboratory confirmed infection, combined with microbiologic confirmation of COVID-19 infection in the participant” |
| [https://clinicaltrials.gov/show/NCT04377646](https://clinicaltrials.gov/show/NCT04377646) “Any COVID-19 related symptoms (cough, fever, headache, vomiting, nausea, dyspnea, diarrhea, smell disorder, conjunctivitis, dizziness)” |
| [https://clinicaltrials.gov/ct2/show/NCT04360122](https://clinicaltrials.gov/ct2/show/NCT04360122) “any symptoms suggestive of COVID19: fever, plus at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure, runny/ blocked nose, plus Laboratory: Sampling of the following will be withdrawn from all participants at beginning and end of the study: COVID 19 IgM (for recent infection) or IgG (for old infection)” |
| [https://clinicaltrials.gov/show/NCT04445428](https://clinicaltrials.gov/show/NCT04445428) “Episodes with self-reported infectious disease morbidity suspected to be caused by COVID (three or more of the following: fever, cough, sore throat, extreme fatigue, loss of smell/taste)” |
| [https://clinicaltrials.gov/show/NCT04452643](https://clinicaltrials.gov/show/NCT04452643) “Incidence of subjects with COVID-19, defined by the presence of: Fever, Any of the respiratory signs and/or symptoms: cough, dyspnea, respiratory failure, runny nose/nasal obstruction, Positive test for SARS-COV-2 (PCR or serology)” |
| [https://clinicaltrials.gov/show/NCT04461379](https://clinicaltrials.gov/show/NCT04461379) “disease defined as positive SARS-Cov-2 test (serology), plus fever (using self-reported questionnaire), or at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure (using self-reported questionnaire)” |
| [https://clinicaltrials.gov/show/NCT04470427](https://clinicaltrials.gov/show/NCT04470427) “The participant must have experienced at least TWO of the following systemic symptoms: Fever (≥ 38°C), chills, myalgia, headache, sore throat, new olfactory and taste disorders” |
| [https://clinicaltrials.gov/show/NCT04471766](https://clinicaltrials.gov/show/NCT04471766) “Self-reported main symptoms of COVID-19 (three or more - fever, cough, fatigue, shortness of breath, loss of smell/taste)” |
| [https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002287-31/ES](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002287-31/ES): “Examine the incidence of typical symptoms of SARS-CoV-2 infection: fever, cough, headache, arthromyalgia, pharyngeal pain, dyspnea, diarrhea, vomiting, abdominal pain, anosmia” |
| [https://clinicaltrials.gov/show/NCT04437693](https://clinicaltrials.gov/show/NCT04437693) “COVID-19 related symptoms, that may include: Temperature over 37.8 degrees Celsius, Shortness of Breath, Cough” |
| [https://clinicaltrials.gov/show/NCT04614948](https://clinicaltrials.gov/show/NCT04614948) “Mild COVID-19 includes: Fever, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, cough, chest congestion, runny nose, wheezing, skin rash, eye irritation or discharge, or chills, without shortness of breath or dyspnea.” |
| [https://clinicaltrials.gov/show/NCT04614948](https://clinicaltrials.gov/show/NCT04614948) “COVID-19 symptoms consistent with those defined by the US FDA harmonized case definition at the time of finalization of this protocol: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea.” |
| [https://clinicaltrials.gov/show/NCT04350931](https://clinicaltrials.gov/show/NCT04350931) “COVID 19 infection in the form of: fever, dry cough, fatigue, & dyspnea” |
| [https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175](https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12175) “defined as I. fever (using a self-reported questionnaire), plus II. at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire)” |
| [https://clinicaltrials.gov/show/NCT04534803](https://clinicaltrials.gov/show/NCT04534803) “fever (as documented in EHR) or at least one sign or symptom of respiratory disease including cough, shortness of breath, respiratory distress/failure (as documented in EHR)” |
| [https://clinicaltrials.gov/show/NCT04349228](https://clinicaltrials.gov/show/NCT04349228) “The rate of COVID19 infections is defined by the occurrence of the clinical signs below: Cough, Dyspnea, Fever, Myalgia, Arthralgia, Rhinorrhea, Anosmia, Asthenia, Fatigability” |
| [https://clinicaltrials.gov/show/NCT04452643](https://clinicaltrials.gov/show/NCT04452643) “WHO definition” |
| [https://clinicaltrials.gov/show/NCT04526821](https://clinicaltrials.gov/show/NCT04526821) “Severity of SARS-CoV-2 infection (asymptomatic, mild, moderate, severe infection), assessed by the World Health Organization definitions” |
Table 5. Symptoms included in definitions of SARS-CoV-2 infection outcomes.

| Symptom                                           | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | Frequency of inclusion in any definition (n = 19) |
|---------------------------------------------------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-------------------------------------------------|
| Fever                                             | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 19                                               |
| Cough                                             | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 18                                               |
| Dyspnoea/shortness of breath/ Difficulty breathing/ respiratory distress/respiratory failure | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 16                                               |
| Rhinorrhoea/coryza/runny or blocked nose          | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 9                                               |
| Loss of smell/anosmia/new olfactory/smell disorder| Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 8                                               |
| Fatigue/extreme fatigue/malaise                   | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 7                                               |
| Headache                                          | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 7                                               |
| Myalgia/muscle pain                               | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 7                                               |
| Sore throat                                        | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 6                                               |
| Chills                                            | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 5                                               |
| Loss of taste/new taste disorder                  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 5                                               |
| Gastrointestinal symptoms/nausea/abdominal pain    | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 5                                               |
| Vomiting                                          | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 4                                               |
| Diarrhoea                                         | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 4                                               |
| Arthralgias                                       | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 3                                               |
| Conjunctivitis/eye irritation/discharge            | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 2                                               |
| Rigors                                            | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 1                                               |
| Dizziness                                         | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 1                                               |
| Arthromyalgia                                     | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 1                                               |
| Pharyngeal pain                                   | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 1                                               |
| Chest congestion                                  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | Y  | 1                                               |
Table 5. Continued

| Symptom            | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
|--------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|
| Wheezing           | Y |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |
| Skin rash          | Y |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |
| Asthenia           |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |

1. ClinicalTrials.gov [Internet]. Identifier NCT04318015, Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA); 2020 Mar 23 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT04318015
2. Rajaasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clin Infect Dis. 2020 Oct 17;ciaa1571. doi: 10.1093/cid/ciaa1571.
3. Clinical Trials Registry India [Internet]. Identifier CTRI/2020/02/024833, Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers – a double blind randomized controlled trial; 2020 Apr 24 [cited 2020 Nov 24]. Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43105
4. ClinicalTrials.gov [Internet]. Identifier NCT04321174, COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR); 2020 Mar 25 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04321174
5. ClinicalTrials.gov [Internet]. Identifier NCT04377646, A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit); 2020 May 6 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04377646
6. ClinicalTrials.gov [Internet]. Identifier NCT04360122, Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19; 2020 Apr 24 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04360122
7. ClinicalTrials.gov [Internet]. Identifier NCT04445428, OPV as Potential Protection Against COVID-19; 2020 Jun 24 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04445428
8. ClinicalTrials.gov [Internet]. Identifier NCT04526443, Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel (Bacmune); 2020 Jun 30 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04526443
9. ClinicalTrials.gov [Internet]. Identifier NCT04461379, Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers; 2020 Jul 8 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04461379
10. ClinicalTrials.gov [Internet]. Identifier NCT04471766, Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention; 2020 Jul 15 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04471766
11. EU Clinical Trials Register [Internet]. Identifier 2020-002287-31, Prevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped wedge trial by clusters. PREVICHARM Study; 2020 May 25 [cited 2020 Nov 24]. Available from: https://www.clinicaltrialregister.eu/ctr-search/trial/2020-002287-31/ES
12. ClinicalTrials.gov [Internet]. Identifier NCT04437693, Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients (HCQ-COVID19); 2020 Jul 18 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04437693
13. ClinicalTrials.gov [Internet]. Identifier NCT04451694, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 1); 2020 Jun 4 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04451694
14. ClinicalTrials.gov [Internet]. Identifier NCT04614948, A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults (ENSEMBLE 2); 2020 Nov 4 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04614948
15. ClinicalTrials.gov [Internet]. Identifier NCT04350931, Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19; 2020 Apr 17 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04350931
16. Pan African Clinical Trials Registry [Internet]. Identifier PACTR202006883882711, Effectiveness of Measles, Mumps and Rubella Vaccine in Health Care Professionals for COVID-19; 2020 Jun 30 [cited 2020 Nov 24]. Available from: https://pactr.samarca.ca/TrialDisplay.aspx?TrialID=12175
17. ClinicalTrials.gov [Internet]. Identifier NCT04534803, BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST); 2020 Sep 1 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04534803
18. ClinicalTrials.gov [Internet]. Identifier NCT04349228, Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals (COVID_2Pro); 2020 Apr 16 [cited 2020 Nov 24]. Available from: https://clinicaltrials.gov/show/NCT04349228.
been reported in areas such as delirium, hearing loss, chronic pelvic pain, and breast reconstruction, with studies concluding the need for consensus on outcomes and their associated measures for use in future clinical trials in these disease areas.19–22

To our knowledge, this is the first study to examine how SARS-CoV-2 infection outcomes are measured in registered COVID-19 prevention trials. However, there are some methodological limitations. Only the Cochrane COVID-19 Study Register https://covid-19.cochrane.org/ was searched to identify COVID-19 prevention trials, which may limit the number of relevant studies identified. The Cochrane register, however, is updated regularly and includes studies identified from six data sources, including ClinicalTrials.gov. Furthermore, although we did not specifically search each of the data sources, we used the trial URL provided in the Cochrane Study Register entry to access the original trial registry entry. Another limitation is the lack of detail about infection outcome definitions reported in the trial registry entries. Where readily available via links within the registry, protocols and published papers were also examined. However, due to resource limitations we did not manually search for protocols and full text papers corresponding to the trials included in this review, meaning some detail on outcome definitions may have been missed and may be readily available in trial protocols thus potentially changing the results of this study. Trialists may have a rationale for their choice of outcome measurements, but this was not included in the registry entry.

The COS-COVID-P study recommended SARS-CoV-2 infection be measured in all COVID-19 prevention trials, regardless of the intervention and setting.9 We found 92% of trials included SARS-CoV-2 infection as an outcome; however, very few reported the rationale for SARS-CoV-2 infection outcome selection and measurement. From the limited details we have regarding rationale, decisions often appear to be based on accessibility of testing and feasibility. This is understandable and will likely be due to circumstances specific to the setting and country where the trial is being conducted. Going forward, we advise trialists to be transparent about their rationale for the definition of SARS-CoV-2

Table 6. SARS-CoV-2 infection outcome definitions by setting: Values are number of trials in each setting with at least one COVID outcome with this definition (% out of total number of trials in this setting).

| SARS-CoV-2 infection outcome definition | Non-specific term | Test only | Symptoms only | Test AND symptoms | Test OR symptoms |
|----------------------------------------|------------------|----------|---------------|------------------|-----------------|
| Close contact with COVID (n = 15)      | 4 (27)           | 6 (40)   | 5 (33)        | 3 (20)           | 0 (0)           |
| Community/adults (n = 37)              | 12 (32)          | 18 (49)  | 7 (19)        | 12 (32)          | 1 (3)           |
| Health care workers (n = 92)           | 16 (17)          | 53 (58)  | 24 (26)       | 21 (23)          | 9 (10)          |
| High risk groups (n = 21)              | 8 (38)           | 9 (43)   | 2 (10)        | 4 (19)           | 2 (10)          |
| Nursing home (n = 10)                  | 4 (40)           | 5 (50)   | 4 (40)        | 5 (50)           | 1 (10)          |
| Police (n = 3)                         | 0 (0)            | 1 (33)   | 2 (67)        | 0 (0)            | 0 (0)           |
| Potential exposure (n = 5)             | 1 (20)           | 3 (60)   | 1 (20)        | 1 (20)           | 0 (0)           |
| Schools (n = 1)                        | 0 (0)            | 1 (100)  | 0 (0)         | 0 (0)            | 0 (0)           |

Table 7. SARS-CoV-2 infection outcome definitions by intervention group: Values are number of trials in each intervention group with at least one COVID outcome with this definition (% out of total number of trials with this intervention).

| SARS-CoV-2 infection outcome definition | Non-specific term | Test only | Symptoms only | Test AND symptoms | Test OR symptoms |
|----------------------------------------|------------------|----------|---------------|------------------|-----------------|
| Behavioural/distancing (n = 3)         | 1 (33)           | 1 (33)   | 1 (33)        | 1 (33)           | 0 (0)           |
| Dietary supplement (n = 19)            | 4 (21)           | 15 (79)  | 3 (16)        | 2 (11)           | 1 (5)           |
| Drug prophylaxis (n = 92)              | 16 (17)          | 51 (55)  | 23 (25)       | 24 (26)          | 9 (10)          |
| Other (n = 12)                         | 5 (42)           | 4 (33)   | 6 (50)        | 0 (0)            | 0 (0)           |
| PPE/physical barrier (n = 4)           | 1 (25)           | 2 (50)   | 2 (50)        | 1 (25)           | 0 (0)           |
| Vaccine (n = 54)                       | 18 (33)          | 23 (43)  | 10 (19)       | 18 (33)          | 3 (6)           |
infection outcomes used when registering and reporting their trials, to improve understanding of the context of their research. The trial registration should include both the rationale for outcome measurement, along with details on how infection will be analysed. In addition, we understand trialists will collect as much data as they consider relevant, but we recommend they develop a coherent statistical analysis plan (SAP) to ensure transparency and reproducibility.23

In the current review, we found two thirds of the studies evaluating behaviour interventions, such as those intended to increase handwashing or SMS text prompts to wear masks, did not include any SARS-CoV-2 infection outcomes. Trials of simple behavioural interventions may be unlikely to measure infection, as their purpose is to modify an individual’s behaviour rather than to directly prevent an individual from acquiring COVID-19. This is in contrast with those of complex interventions that include a behavioural component (e.g. donning standardised PPE versus specialised PPE; or hand washing with soap versus using alcohol wipes) where the overarching aim is still likely to be prevention of SARS-CoV-2 infection.

Alongside SARS-CoV-2 infection, the COS-COVID-P study also led to the inclusion of intervention-specific harms in the COS for all COVID-19 prevention research studies. The current review did not examine this aspect. Determining these harm outcomes requires agreement amongst those with expertise in the specific interventions being tested. It may be that the harms are similar within certain intervention types, e.g. drug prophylaxis and vaccines. However, expert opinion will be necessary to determine the relevance of such an approach, but consistency will be important to avoid research waste and to facilitate evidence synthesis in which the results of studies of similar interventions are compared, contrasted and, where appropriate, combined. There may also be a need for COS for studies in specific settings. For example, a COS evaluating interventions for the prevention of COVID-19 transmission in care homes (COS-COVID-PCARE) is

Table 8. Rationale provided for definition of SARS-CoV-2 infection outcomes.

| Rationale |
|-----------------------------------------------|
| [https://clinicaltrials.gov/show/NCT04346329](https://clinicaltrials.gov/show/NCT04346329) “For this, once the informed consent form is signed, the molecular test for the diagnosis of SARS-CoV-2 infection by RT-PCR will be carried out every 4 days in order to determine as closely as possible the moment the participant become positive.” |
| [https://clinicaltrials.gov/ct2/show/NCT04519125](https://clinicaltrials.gov/ct2/show/NCT04519125) “To determine the occurrence of infection with the virus the study will use both molecular tests that detect the presence of viral genes in respiratory secretions, and serological tests that detect the response of the immune system to the virus.” |
| [https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24](https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001448-24) “Testing and criteria for diagnosis COVID-19 is likely to rapidly evolve over the course of this trial and will vary internationally. Therefore, the following pragmatic definitions will be applied: o Confirmed positive test for COVID-19: either a laboratory test (performed according to each participating hospital’s local protocols) or a computed tomography (CT) thorax scan (based on individual radiologist interpretation and diagnosis) that confirms COVID-19 diagnosis. o Confirmed negative test for COVID-19: a laboratory test (performed according to each participating hospital’s local protocols) that is negative for COVID-19 diagnosis.” |
| [https://pubmed.ncbi.nlm.nih.gov/33001138](https://pubmed.ncbi.nlm.nih.gov/33001138) “A recent randomized trial for postexposure COVID-19 prophylaxis with a 5-day course of hydroxychloroquine did not demonstrate clinical benefit. However, the composite primary outcome measure for this study included symptoms consistent with infection without laboratory confirmation; most patients did not have assessment of SARS-CoV-2 infection by reverse-transcriptase polymerase chain reaction (RT-PCR), raising concerns of type II error from asymptomatic participants. We sought to test the hypothesis that administering daily hydroxychloroquine would prevent SARS-CoV-2 infection in hospital-based HCWs over 8 weeks of exposure via RT-PCR testing of nasopharyngeal (NP) swabs and serologic antibody testing from participants at baseline, 4 weeks, and 8 weeks of treatment.” |
| [https://clinicaltrials.gov/show/NCT04328441](https://clinicaltrials.gov/show/NCT04328441) “The aim of our trial is to ensure the continuity of health care, and this is the reason for this pragmatic primary endpoint. Moreover, BCG vaccine is expected to reduce all-cause infections and not only COVID-19. Moreover, this was a non-funded study, precluding intensive personal follow-up, and the measurement of absenteeism as this was considered relevant, and immediately obvious…. One of the secondary endpoints in the HCW trial is documented COVID-19 infection. It is important to keep in mind that health workers in the Netherlands are structurally examined for the presence of COVID-19 in case of any respiratory symptoms or in case of fever. Therefore, we expect a high detection rate.” |
| [https://pubmed.ncbi.nlm.nih.gov/33068425](https://pubmed.ncbi.nlm.nih.gov/33068425) “Given limited availability of outpatient PCR testing in many jurisdictions during our study period, particularly in April 2020, probable Covid 19 based on Covid-19-compatible symptoms was included in the composite primary endpoint.” |
| [https://pubmed.ncbi.nlm.nih.gov/33068425](https://pubmed.ncbi.nlm.nih.gov/33068425) “To ensure feasibility, facilitate speed, and limit costs, we aim to base our outcome measures on routinely collected data, to the extent possible. Testing for COVID-19 takes place continuously and consistently across the country. All suspect cases have access to testing and laboratories use valid tests meeting quality assurance requirements.” |
currently under development. Building on the COS-COVID-P study, the COS-COVID-PCARE study is proposing to develop a supplementary specific module for COVID-19 prevention in care homes.24

Conclusion
We have described the variation in the selection and measurement of SARS-CoV-2 infection outcomes, with illustrated examples from on-going trials across various settings and interventions. As knowledge about COVID-19 increases over time, this is leading to improvements in the design of studies and reporting. Nevertheless, our findings highlight the need for clarity, transparency and standardisation of measures of SARS-CoV-2 infection. It is now timely to highlight these issues, to improve the collection of infection data to inform key public health decisions.

Data availability
Underlying data
University of Liverpool Data Catalogue: SARS-CoV-2 infection outcomes. https://doi.org/10.17638/datacat.liverpool.ac.uk/1279.24

This project contains the following underlying data:

- The dataset consists of COVID-19 prevention trials, with the following data extracted for each trial: intervention type (e.g. drug, vaccine, behavioural), intervention (as described verbatim), setting (i.e. population of interest), SARS-CoV-2 infection outcomes (as described verbatim), SARS-CoV-2 infection outcome definition (i.e. how SARS-CoV-2 infection would be measured), whether or not the SARS-CoV-2 infection outcome was specified as being a primary or secondary outcome, and the rationale provided for SARS-CoV-2 infection outcome measurement selection.

Data are available under the terms of the Creative Commons: Attribution 3.0 license.

Acknowledgements
In addition to article authors, members of the COS-COVID-P Study Steering Committee include: Elie Akl (American University of Beirut, Lebanon); Aneel Bhangu (University of Birmingham, UK); Deborah Caldwell (University of Bristol, UK); Mike Clarke (Queen’s University Belfast, UK); Jonathan Craig (Flinders University, Australia); Liang Du (Cochrane China); Adam Finn (University of Bristol, UK); Ella Flemyng (Cochrane, UK); Atle Fretheim (Norwegian Institute of Public Health, Norway); Claire Goodman (University of Hertfordshire, UK); Lars Hemkens (University of Basel, Switzerland); Tammy Hoffman (Bond University, Australia); John Ioannidis (Stanford University, USA); Martin Knapp (London School of Economics, UK); David Lalloo (Liverpool School of Tropical Medicine, UK); Susan Michie (UCL, UK); Richard Morley (Cochrane, UK); Malcolm G Semple (University of Liverpool, UK); Maureen Smith (Cochrane Consumer Network, Canada); Allison Tong (University of Sydney, Australia); Sean Tunis (Center for Evaluation of Value and Risk in Health, USA); Junhua Zhang (Tianjin University of Traditional Chinese Medicine, China).

References
1. COVID-19 Research Priorities Identified by the Global Research Community. [cited 20-7-20]. Reference Source
2. Cochrane COVID-19 Study Register [Internet]. [cited 17 February 2021]. Reference Source
3. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al.: Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020; (9). PubMed Abstract | Publisher Full Text | Free Full Text
4. Chu DK, Aki EA, Duda S, et al.: Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020; 395(10242): 1973-87. PubMed Abstract | Publisher Full Text | Free Full Text
5. Verbeek JH, Rajamaki B, Ijaz S, et al.: Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database Syst Rev. 2020; (4). PubMed Abstract | Publisher Full Text | Free Full Text
6. Krishnaratne S, Pfadenhauer LM, Coenen M, et al.: Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review. (1469-493X (Electronic)). PubMed Abstract | Publisher Full Text
7. Williamson PR, Altman DG, Bagley H, et al.: The COMET Handbook: version 1.0. Trials. 2017; 18(Suppl 3): 280. Epub 2017/07/07. PubMed Abstract | Publisher Full Text | Free Full Text
8. Avery K, Macefield R, Gorst S, et al.: Developing a core outcome set for COVID-19 prevention interventions: the COS COVID-P study. In: Collaborating in response to COVID-19: editorial and methods initiatives across Cochrane. Cochrane Database Syst Rev. 2020; 12(Suppl 1): 15-18. Publisher Full Text
9. Stegeman I, Ochodo EA, Guleid F, et al.: Routine laboratory testing to determine if a patient has COVID-19. (1469-493X (Electronic)). PubMed Abstract | Publisher Full Text | Free Full Text

10. Stryuy T, Deeks JJ, Dinnes J, et al.: Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. (1469-493X (Electronic)). PubMed Abstract | Publisher Full Text | Free Full Text

11. ClinicalTrials.gov [Internet]: Identifier NCT04330352, Mindfulness-based “STOP (Stop, Take a Breath, Observe, Proceed) Touching Your Face” Intervention. 2020 Apr 1 [cited 2020 Nov 24]. Reference Source

12. ClinicalTrials.gov [Internet]: Identifier NCT04373096, Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers; 2020 May 4 [cited 2020 Nov 24]. Reference Source

13. EU Clinical Trials Register [Internet]: Identifier 2020-001448-24, Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19; 2020 Apr 15 [cited 2020 Nov 24]. Reference Source

14. Fretheim AA-O, Flata M, Steens A, et al.: COVID-19: we need randomised trials of school closures. (1470-2738 (Electronic)). PubMed Abstract | Publisher Full Text

15. Abella BS, Jolkovsky EL, Biney BT, et al.: Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. (2168-6114 (Electronic)). PubMed Abstract | Publisher Full Text | Free Full Text

16. Rajasgingham R, Bangdivala AS, Nicol MR, et al.: Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. LID - 10.1093/cid/ciaa1571 [doi] LID - ciaa1571. (1537-6597 (Electronic)). PubMed Abstract | Publisher Full Text | Free Full Text

17. Mathioudakis AG, Fally M, Hashad R, et al.: Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review. 2020; 10(12): 350. PubMed Abstract | Publisher Full Text | Free Full Text

18. Rose L, Agar M, Burry L, et al.: Reporting of Outcomes and Outcome Measures in Studies of Interventions to Prevent and/or Treat Delirium in the Critically Ill: A Systematic Review. 2020; 48(4): e316–e24. PubMed Abstract | Publisher Full Text

19. Ghai V, Subramanian V, Jan H, et al.: A systematic review on reported outcomes and outcome measures in female idiopathic chronic pelvic pain for the development of a core outcome set. 2021; 128(6): 628–34. PubMed Abstract | Publisher Full Text

20. Hill-Feltham PR, Johansson ML, Hodgetts WE, et al.: Hearing outcome measures for conductive and mixed hearing loss treatment in adults: a scoping review. Int J Audiol. 2020; 1–7. PubMed Abstract | Publisher Full Text

21. Davies CF, Maclefield R, Avery K, et al.: Patient-Reported Outcome Measures for Post-mastectomy Breast Reconstruction: A Systematic Review of Development and Measurement Properties. Ann Surg Oncol. 2021; 28(1): 386–404. PubMed Abstract | Publisher Full Text | Free Full Text

22. Gamble C, Krishan A, Stocken D, et al.: Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017; 318(23): 3397–33. PubMed Abstract | Publisher Full Text

23. Hood K, Williamson P, Wood F, et al.: A Core Outcome Set for studies evaluating interventions for the prevention of COVID-19 transmission in care homes (COS-COVID-PCARE). Reference Source

24. Dodd S: SARS-CoV-2 infection outcomes. [Data Collection]. Data Catalogue. 2021. Publisher Full Text
Open Peer Review

Current Peer Review Status: ✔️

Version 1

Reviewer Report 13 July 2021

https://doi.org/10.5256/f1000research.55776.r86394

© 2021 Tyler N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Natasha Tyler

Faculty of Biology, Medicine and Health, NIHR Greater Manchester Patient Safety Translational Research Centre (PSTRC), University of Manchester, Manchester, UK

Summary:

The authors present a systematic review to assess outcome reporting in Covid-19 infection outcome trials. They review the Cochrane COVID-19 Study Register. They found heterogeneity in the SARS-CoV-2 infection outcome measurement choices in prevention trials.

Is the work clearly and accurately presented and does it cite the current literature?

The introduction is clearly written and accurately presented. The paper as a whole is clear and concise. As many of us are experiencing research and evidence concerning Covid become quickly outdated. I would recommend searching the Cochrane database again for a more up to date figure for reference 2 in the introduction. As the evidence moves so quickly in regards to Covid, I think it needs to be addressed in the limitations that this review concerns lots of studies that happened in a crisis period and that future studies might have better outcome/rationale reporting, and suggesting learning points from this.

Is the study design appropriate and is the work technically sound?

The systematic review design is appropriate and follows the standard procedures for COS reviews. A minor concern would be the rationale component, there were only 7 reported rationale, so the research does not answer one of the key research questions/aims.

The aim of this study is to review SARS-CoV-2 infection outcomes in registered COVID-19 prevention trials and examine the reported rationales for choice of outcome measurement. Our intention is that this will inform optimal methods for the design of future studies.
Whilst the authors describe how future trials can be improved through reporting rationale, there is little acknowledgement about how this research question/aim is not addressed in the results of this paper. Highlighting the limitations of using a systematic review method in this way would be beneficial and perhaps suggesting alternative methods in the discussion (i.e. stakeholder consultation) in similar research.

My other query would be in regards to the behavioural interventions, if you are looking at outcomes for interventions that prevent an individual from acquiring covid-19 (infection outcomes) would it not be best to remove the behaviour modification interventions from this review or present them separately, it seems to me this should have perhaps been an inclusion/exclusion criteria. I would assume this may reduce some of the heterogeneity in outcomes also.

**Are sufficient details of methods and analysis provided to allow replication by others?**

The methods are detailed and analysis thorough and replicable.

**If applicable, is the statistical analysis and its interpretation appropriate?**

Statistical analysis and interpretation are appropriate.

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Conclusions are supported by the results. My only concern is that whilst the authors argue the limitations with the trials reviewed there is not much discussion about the limitations of this study, some I have mentioned above. The heterogeneity in reporting infection outcomes, could be related to studies being conducted before testing was established in many countries and acknowledging that the studies reviewed were conducted during crisis and that future studies may provide better rationale for outcomes as we move forward. Also, advice/suggestions about how trialists could improve outcome decisions in pandemic situations (when the development of adequate infection testing is developing) to improve homogeneity of outcomes would be a useful addition to the literature.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Core outcome set development

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com